RT Conference Proceedings
T1 Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
A1 Sequist, L.
A1 Gray, J.
A1 Harb, W.
A1 Doebele, R.
A1 Modiano, M.
A1 Jackman, D.
A1 Baggstrom, M.
A1 Atmaca, A.
A1 Felip, E.
A1 Provencio, M.
A1 Cobo Dols, M.
A1 Adiwijaya, B.
A1 Kuesters, G.
A1 Kamoun, W.
A1 Andreas, K.
A1 Pipas, J.
A1 Santillana, S.
A1 Cho, B. C.
A1 Park, K.
A1 Shepherd, F.
K1 biomarker
K1 Seribantumab
K1 Heregulin
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-10-01
LK https://hdl.handle.net/10668/24369
UL https://hdl.handle.net/10668/24369
LA en
DS RISalud
RD Apr 17, 2025